Arthur Combs, Md Email & Phone Number

Technology, Clinical and Business opportunity assessment for medical devices, biotechnology and pharmaceuticals. Due diligence or investment opportunities, business plan review, assistance with capital formation.Representative Consulting Assignments:Bay City Capital (VC) - Life Sciences VC Investment Opportunity AssessmentH-P Medical Systems - Integrated Ventilation ManagementAgilent Technologies - Tight Glycemic Control Implementation and InstrumentationPhilips Medical Systems - Molecular Diagnostics – Target Markets, Molecular SolutionsSomaLogic, Inc. - Aptamer-based Molecular Diagnostics for ICU ApplicationsEdwards Life Sciences - Strategy for Noninvasive Cardiac Output Monitoring Diametrics Medical - Continuous ABG Monitoring for Ventilation ManagementMattson Jack - Medical Director, Pharmaceutical Consulting Firm Mallinckrodt, Inc. - Use Case development for Imaging Solutions Everest Biomedical - Noninvasive Medical Devices and Diagnostics Glysure - Continuous Blood Glucose Monitoring for ICU ApplicationsNova Biomedical - Critical Care POC and Laboratory DiagnosticsMC10 Inc. - Wearables, Real World Data, Continuomics and Drug DevelopmentHealth2047 - Due Dilignece, EIR asignments, Investment assessments

Developed and presented critical messages for wearable technology, Real World Data, and "Continuomics." Conducted Pivotal Trial for FDA 510(k) product clearance. Developed comprehensive translational value propositions across therapeutic areas and specific disease entities instrumental in closing large clinical trials contracts with top Pharma, BioTech and Med Device companies. Developed strong research relationships with academia, clinicians and professional societies. MC10 was acquired by Dessault-MediData.

Successfully Raised more than $20 million in private investments and public (NIH SBIR) support for Grove’s noninvasive blood glucose measurement technology. Transformed the Company from an academic research endeavor to a true product development firm. Evolved the Board to world class with 4 independent Directors and assembled an unrivaled Scientific Advisory Board. Led technology development from science concept to a fully integrated noninvasive glucose meter prototype, tested in both in-house (NEIRB) and University (UMass and Yale) clinical trials. Led the Company to a Massachusetts Life Sciences Accelerator Award (2011), and 2 time abstract presenter at ATTD (2013, 2015). Expanded the Company’s IP estate to 9 issued patents, 2 pending and 5 new disclosures. Successfully obtained extramural strategic support from “Big Pharma” Sanofi for new technology platform initiative. Positioned the Company for commercialization of its first – and the world’s first - noninvasive glucose monitor. Recruited and hired a multi-disciplinary product development team, and increased Company Valuation form $1 million to $40 million. Continuously created shareholder value and charted a clear path and strategy to commercialization opportunities.

Raising 4 million Euro in Venture Capital as part of the BMEYE leadership team for a noninvasive cardiac output and hemodynamic monitor. Led and placed research units in 10 high profile academic sites across the United States opening up market opportunities. Segmented the market and go-to-market strategy based on unmet needs, diagnostic protocols and understanding of clinical procedures, volumes and reimbursement. Developed all sales training materials for each clinical market segment required for the Company’s launches in European countries. Instrumental in securing CE Mark certification in the EU and 510(k) clearance in the U.S. BMEYE was successfully acquired by Edwards Life Sciences at a 10X multiple on invested capital.

Assisted Everest in raising $7.5 million in Venture Capital for a suite of noninvasive medical products including an infant hearing screening device based on oto-acoustic emissions and ABR (AUDIOScreenerTM); an anesthesia monitoring device based on high frequency EEG (SNAP IITM); and a leading edge automated neurodiagnostic device based on quantitative EEG (BrainScopeTM).Co-inventor on the seminal BrainScopeTM patent. Architect of technology and prototype development, and the first human clinical trials at Washington University. Conducted progressive clinical trials of SNAP II in operating rooms across the country, and a landmark “isolated forearm technique” study of existing anesthesia monitoring technology vs. high frequency EEG for predicting consciousness during neuromuscular blockade. AUDIOScreener was sold to VIASYS; BrainScope spun out as a separate company (www.brainscope.com); and Everest was acquired by Stryker International in 2005.

Led a staff of 350 engineers and scientists worldwide in the U.S., Europe and Canada with a $76 million annual budget, inclusive of the Nellcor Puritan-Bennett, Shiley, and Mallinckrodt Anesthesia businesses. Successfully competed for and negotiated large GPO contracts (Premier, Novation) for Nellcor Oximetry valued at >$100 million. Awarded “Executive of the Year 2000” by Nellcor Puritan Bennett. Created and implemented an integrated ventilation management vision melding Mallinckrodt’s airway, oximetry and ventilation products to enhance ICU management and create new revenue opportunities. Member of the General Management Committee (top 50 employees in a company of 13,000), and the Technology Management Committee. Nellcor’s PMA noninvasive fetal pulse oximeter, Puritan Bennet’s flagship 840 ventilator (510(k)), and Nellcor’s 4th generation motion tolerant pulse oximetry (510 (k)) were all cleared to market while serving as senior management. Presented to National Sales Meeting, Annual Shareholders Meeting, Wall Street Analysts and Board of Directors. Mallinckrodt was acquired by TYCO International in 2000.

Bachelor Of Science - Bs, Pre-Professional Studies

Doctor Of Medicine - Md

Education record

Education record